Bavarian Nordic initiates phase II trial for Covid-19 vaccine

In a long-awaited phase II trial, Bavarian Nordic starts testing the efficacy of its Covid-19 vaccine for reinforcing existing immunity in persons either previously vaccinated or infected.

Photo: Bavarian Nordic / PR

After having recently published promising data for its ABNCoV2 vaccine against Covid-19, Bavarian Nordic now begins a phase II trial for its candidate, Bavarian informs in a press release Monday morning.

"We are pleased to continue development of our Covid-19 vaccine candidate by starting this phase II trial, which we expect will confirm the high levels of neutralizing antibodies already shown by ABNCoV2 in pre-clinical studies as well as a phase I clinical trial," writes Bavarian Nordic Chief Executive Paul Chaplin in the statement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs